GSE89593 Transcriptomic profiling of human Tumour Associated Macrophages from Non-Small Cell Lung Cancer show dual M1 and M2 functions and recruit CD8+ T cells by production of CXCL9

Contributors : P Vijayanand ; C H Ottensmeier ; Tilman Sanchez-Elsner ; Eva M Garrido-MartinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTumour Associated Macrophages (TAMs) are considered as functionally inactive or re-shaped by the tumour into a pro-tumour M2 phenotype. There is lack of transcriptomic data of TAMs purified from human cancers. We performed transcriptomic analyses on TAMs isolated from human NSCLC in comparison with matched tumour-free lung tissue macrophages from the same patients. TAMs are essentially M2 activated, but in some patients TAMs also exhibit a strong anti-tumour M1 activity: (i) TAMs with a high Antigen-Presentation signature are associated with a better prognosis, (ii) TAMs expressing high levels of CXCL9 recruit more CD8+ T-cells in lung adenocarcinoma patients and are associated to improved survival. Immunotherapy enhancing TAM expression of CXCL9 and Antigen-Presenting molecules could enhance the immune response to tumours.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

In this study, we investigated genetic variations in EGFR and their association with the clinical and pathological factors of NSCLC. MATERIAL AND METHODS Clinical cases (331 patients) and The Cancer Genome Atlas (TCGA) cases (1040 patients) were selected and analyzed using the refractory mutation systems cBioPortal and the Tumor Immune Estimation Resource (TIMER). RESULTS EGFR mutation frequencies were 54.4% (180 of 331 patients) and 8.0% (83 of 1040 patients) in the clinical and TCGA cohorts, respectively. EGFR mutations were strongly associated with smoking and pathology (P≤0.05) in the clinical cohort, and with gende...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Background: The use of antibodies against PD-1 or PD-L1 are increasing used for non-small cell lung cancer (NSCLC) therapy. Biopsies can show limitations determining its expression. Endobronchial ultrasound-guided transbronchial needle aspirate (EBUS-TNBA) has demonstrated its rentability for diagnosis and staging of lung cancer, but information about its performance for PD-L1 is limited. The aim of our study was to analyze the ability of EBUS-TBNA samples to identify the expression of PD-L1.Methods: From Apr’17 to Aug’18, we evaluated its expression in 76 cell blocks obtained by EBUS-TBNA. Minimum of 3 punctur...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Interventional pulmonology Source Type: research
Conclusion: Bronchoscopic re-biopsy for progressive lung cancer is feasible and safe. Histological change can be detected in a considerable number of patients, which is potentially valuable information for guidance of subsequent treatment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Nowadays, cancer immunotherapy is rapidly evolving and monoclonal antibodies targeting the programmed death-1 receptor (PD-1)/PD ligand 1 (PD-L1) pathway have been approved for the treatment of NSCLC; however, there is lack of evidence regarding the current use of PD-L1 analysis in the everyday clinical practice.For this purpose we conducted a retrospective observational study in our lung cancer oncology unit. Eligible patients were adults of both sexes with non-small cell lung cancer who were treated in our department from April 2017 through December 2018. In total 123 patients were investigated regarding PD-L1 expression...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Introduction: The EBUS-TBNA is a minimally invasive technique widely used in the diagnosis, staging and immunohistochemistry analysis of lung cancer.1PDL-1 is a checkpoint on NSCLC that can be targeted with immunotherapy.2Routine PDL-1 testing was introduced at Oxford University Hospital NHS Foundation Trust (OUHFT) in 2017 and it is unclear if EBUS-TBNA provides adequate tissue for testing. In our current practice at the OUHFT, all NSCLC cases (Squamous Cell Lung Carcinoma and Lung Adenocarcinoma) identified on cytopathology are subsequently tested for PDL-1 tumour percentage score (TPS). The aim of this study was to see ...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusion: These data suggests that antibiotics may reduce effectiveness of IO in lung cancer patients when prescribed up to three months before initiation of treatment. The authors intend to underscore the importance of prescribing antibiotics in lung cancer patients only when strictly necessary, especially if IO is a therapeutic option.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Introduction: Treatment of Non-small Cell Lung Cancer (NSCLC) underwent notable evolution during the last 15 years. New drugs have been introduced, including pemetrexed, biologicals and immunotherapy, resulting in improvement of outcomes.Aims: We aimed to compare the probability of 2-year survival (2YS) between patients with NSCLC treated in years 2011-12 and 2015-16 and analyze the factors associated with higher probability of 2YS.Methods: Prospective data from the Czech TULUNG registry (a multicenter registry of NSCLC patients treated with personalized treatments) were used. We compared the data of NSCLC patients that st...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
ConclusionsWe review the literature on pericardial effusion under nivolumab to further discuss the hallmarks of pericardial effusion under nivolumab and the management of nivolumab therapy in this situation. In conclusion, pericardial effusion as an immune-related adverse event under nivolumab appears less rare than initially thought and may require particular attention.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsLAT and treatment beyond progression for oligo-progression after initial tumor response to anti-PD1 treatment provide encouraging survival outcomes in selected stage IV NSCLC patients.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureF. Guisier: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: MSD / Merck US; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (institution): Boehringer Ingelheim. R. Gervais: Honoraria (self), Advisory / Consultancy: AstraZenec...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe SMARCA4 catalytic ATPase, can be inactivated by several types of genomic alterations (GA) in NSCLC. SMARCA4 deficient (d) NSCLC is an aggressive subtype of primary lung adenocarcinoma that is often confused with metastatic disease to the lung.MethodsFrom a series of 40,319 clinically advanced NSCLC, 2,840 (7%) SMARCA4d and 37,479 (93%) SMARCA4i cases underwent hybrid capture-based CGP using FFPE material. Microsatellite instability (MSI) was determined on 114 loci and tumor mutational burden (TMB) and (mutations (mut) per/ Mb) was determined on 1.1 Mbp of sequenced DNA. PD-L1 expression was measured b...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer